Danazol therapy in haemophilia

Area of Science:

• Hematology
• Coagulation Disorders
• Pharmacology

Background:

• Haemophilia A and Christmas disease are inherited bleeding disorders caused by deficiencies in coagulation factors VIII and IX, respectively.
• Current treatments aim to replace missing factors or manage bleeding episodes.
• Danazol, an androgen derivative, has been investigated for its potential effects on hemostasis.

Purpose of the Study:

• To evaluate the effects of danazol on hemostatic variables and bleeding tendency in patients with severe haemophilia A and moderately severe Christmas disease.
• To assess changes in activated partial thromboplastin time (APTT), euglobulin clot lysis time (ECLT), and coagulation factor levels (VIII and IX) during danazol therapy.

Main Methods:

• A double-blind, cross-over trial was conducted involving three patients with severe haemophilia A and one patient with moderately severe Christmas disease.
• Patients received danazol and placebo in a randomized sequence.
• Hemostatic variables, including APTT, ECLT, and factor VIII/IX levels, were measured.

Main Results:

• Danazol therapy resulted in a significant shortening of the activated partial thromboplastin time (APTT).
• Euglobulin clot lysis time (ECLT) was also shortened during danazol treatment.
• No consistent changes were observed in factor VIII and IX levels.
• There was no reported improvement in the overall bleeding tendency despite the observed changes in APTT and ECLT.

Conclusions:

• Danazol demonstrates a potential to influence certain in vitro measures of coagulation and fibrinolysis, as indicated by shortened APTT and ECLT.
• The drug did not consistently increase factor VIII or IX levels in these patients.
• Danazol therapy did not lead to a clinical improvement in bleeding tendency for individuals with haemophilia A or Christmas disease.